Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
April 24, 2024 10:00 ET
|
Autolus Therapeutics plc
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts...
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
March 07, 2024 16:01 ET
|
MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 05, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024 17:01 ET
|
Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Goliath Discovers Extensive Mineralization in Multiple Outcrops Over 500 Meters on the Icefields That Remains Wide Open - Golden Triangle, B.C.
August 28, 2023 07:08 ET
|
Goliath Resources Limited
2023 Icefields Exploration Highlights: Three (3) new zones consisting of sulphide-rich breccia, stockwork and veins in shear zones have been discovered on the icefields claim blocks of the Golddigger...
CORRECTION -- Goliath Commences Drilling at New Gold-Copper Porphyry and High-Grade Gold Breccia Targets at Its Lucky Strike Property Near Terrace, British Columbia
August 21, 2023 08:48 ET
|
Goliath Resources Limited
TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (Frankfurt: B4IF), please note that a...
Goliath Commences Drilling at New Gold-Copper Porphyry and High-Grade Gold Breccia Targets at Its Lucky Strike Property Near Terrace, British Columbia
August 21, 2023 07:08 ET
|
Goliath Resources Limited
BULLSEYE GOLD-COPPER PORPHYRY – ~1,000 Metres Diamond Drilling, Highlights: The Bullseye porphyry is a drill ready target that shows all the right components for an extensive gold-copper porphyry...
Goliath Intercepts 23 Meters* of 21.08 g/t AuEq, Including 14 Meters* of 33.75 g/t AuEq at Surebet Golden Gate Feeder Zone, Golden Triangle, B.C
August 15, 2023 10:18 ET
|
Goliath Resources Limited
Drill Highlights: GD-23-157 is a 485 gram x meter AuEq hole (15.59 troy ounces gram meter AuEq) collared from Cliff Pad within the Golden Gate Feeder Zone that intercepted Visible Gold mineralization...
Second Visible Gold Hole Drilled From Cliff Pad at Goliath's Surebet Golden Gate Feeder Zone and 19.87 Meters* of Significant Mineralization, Golden Triangle, B.C.
July 24, 2023 07:00 ET
|
Goliath Resources Limited
Drill Hole GD-23-135 Highlights: Visible Gold has been intercepted at 60.91 meters within the Surebet Golden Gate Feeder Zone and is the second hole drilled from Cliff Pad in 2023 to contain...